Search results for "type II"

showing 10 items of 607 documents

Disease management of type 2 diabetes: a follow-up analysis in a sanitary district of Sicily

2011

AIM:The aim of this paper was to analyze the Disease management of type 2 diabetes in a sanitary district of the Sicily Region (Italy). METHODS: In a population of 9 698 subjects, we selected patients with known type 2 diabetes: a cohort of 385 subjects, (206 women and 179 men) following up for one year. Prevalence of type 2 diabetes in the analyzed population was 3.97%. A great lot of cohort was on a diet. RESULTS: After one year, a per cent reduction of obese and overweight subjects was observed. No differences were observed for Body Mass Index (BMI) at the beginning and at the end of the study. After one year, through educational meetings with the doctor, a significant increase of knowle…

Type II NIDM Prevention Risk Factors
researchProduct

Type II Odontoid Fracture: a case series highlighting the treatment strategies

2019

Background: A type II odontoid fracture, if unstable, can cause spinal cord damage. In this case, it is essential to choose the correct treatment—but the issues of what the correct treatment is and which of the different surgical options is best are quite controversial. In this paper we present strategies for treatment of type II odontoid fracture. Materials and Methods: Thirty consecutive cases of type II odontoid fracture were treated at the Division of Neurosurgery at Villa Sofia Hospital in Palermo (23 cases) and at the Neurosurgical Clinic, University Hospital of Palermo (seven cases), from January 2011 to August 2016. Four patients were treated with external immobilization. Twenty-six…

Type II odontoid fracturemedicine.medical_specialtyC1–C2 instabilitySettore MED/27 - Neurochirurgiabusiness.industryBone ScrewExternal FixatorSpinal cord030218 nuclear medicine & medical imagingSurgeryFracture Fixation InternalOdontoid Proce03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureC1–C2 articular screwFracture FixationmedicineSpinal FracturesTreatment strategybusinessOdontoid screw030217 neurology & neurosurgeryHumanOdontoid fracture
researchProduct

Human inducible nitric oxide synthase (iNOS) expression depends on chromosome region maintenance 1 (CRM1)- and eukaryotic translation initiation fact…

2012

Human inducible nitric oxide synthase (iNOS) is regulated on the expressional level mostly by post-transcriptional mechanisms modulating the mRNA stability. Another important step in the control of eukaryotic gene expression is the nucleocytoplasmic mRNA transport. Most cellular mRNAs are exported via the TAP/Nxt complex of proteins. However, some mRNAs are transported by a different mechanism involving the nuclear export receptor CRM1. Treatment of DLD-1 cells with the CRM1 inhibitor leptomycin B (LMB) or anti-CRM1 siRNAs reduced cytokine-induced iNOS expression. We could demonstrate that the iNOS mRNA is exported from the nucleus in a CRM1-dependent manner. Since CRM1 itself does not poss…

Untranslated regionCancer ResearchPhysiologyClinical BiochemistryActive Transport Cell NucleusNitric Oxide Synthase Type IIReceptors Cytoplasmic and NuclearKaryopherinsBiologyenvironment and public healthBiochemistryRNA TransportEukaryotic translationCell Line TumorRibavirinGene expressionP-bodiesHumansMRNA transportRNA MessengerLuciferasesNuclear export signalAnalysis of VarianceMessenger RNAfungiEIF4EMolecular biologyEukaryotic Initiation Factor-4Elipids (amino acids peptides and proteins)Nitric Oxide
researchProduct

Post-transcriptional regulation of the human inducible nitric oxide synthase (iNOS) expression by the cytosolic poly(A)-binding protein (PABP).

2012

Affinity purification using the 3'-untranslated region (3'-UTR) of the human inducible nitric oxide synthase (iNOS) mRNA identified the cytosolic poly(A)-binding protein (PABP) as a protein interacting with the human iNOS 3'-UTR. Downregulation of PABP expression by RNA interference resulted in a marked reduction of cytokine-induced iNOS mRNA expression without changes in the expression of mRNAs coding for the major subunit of the RNA polymerase II (Pol 2A) or β2-microglobuline (β2M). Along with the mRNA also iNOS protein expression was reduced by siPABP-treatment, whereas in the same cells protein expression of STAT-1α, NF-κB p65, or GAPDH was not altered. Reporter gene analyses showed no …

Untranslated regionCancer ResearchSmall interfering RNAFive prime untranslated regionPhysiologyClinical BiochemistryDown-RegulationNitric Oxide Synthase Type IIBiologyBiochemistryPoly(A)-Binding ProteinsCell Line TumorPoly(A)-binding proteinHumansRNA MessengerRNA Processing Post-TranscriptionalPost-transcriptional regulation3' Untranslated RegionsAU-rich elementMessenger RNABinding SitesThree prime untranslated regionMolecular biologyMutationbiology.proteinCytokinesNitric oxide : biology and chemistry
researchProduct

Involvement of KSRP in the post-transcriptional regulation of human iNOS expression–complex interplay of KSRP with TTP and HuR

2005

We purified the KH-type splicing regulatory protein (KSRP) as a protein interacting with the 3'-untranslated region (3'-UTR) of the human inducible nitric oxide (iNOS) mRNA. Immunodepletion of KSRP enhanced iNOS 3'-UTR RNA stability in in vitro-degradation assays. In DLD-1 cells overexpressing KSRP cytokine-induced iNOS expression was markedly reduced. In accordance, downregulation of KSRP expression increases iNOS expression by stabilizing iNOS mRNA. Co-immunoprecipitations showed interaction of KSRP with the exosome and tristetraprolin (TTP). To analyze the role of KSRP binding to the 3'-UTR we studied iNOS expression in DLD-1 cells overexpressing a non-binding mutant of KSRP. In these ce…

Untranslated regionRNA StabilityTristetraprolinNitric Oxide Synthase Type II610 Medicine & healthRNA-binding proteinBiologyImmediate early proteinArticleGene Expression Regulation EnzymologicELAV-Like Protein 1Immediate-Early ProteinsTristetraprolinCell Line TumorGeneticsHumansRNA Messenger610 Medicine & healthPost-transcriptional regulation3' Untranslated RegionsRegulation of gene expressionMessenger RNAThree prime untranslated regionRNA-Binding ProteinsMolecular biologyDNA-Binding ProteinsELAV ProteinsAntigens SurfaceMutationTrans-ActivatorsCytokinesNitric Oxide SynthaseNucleic Acids Research
researchProduct

In Vivo Modulation of Angiogenesis and Immune Response on a Collagen Matrix via Extracorporeal Shockwaves

2020

The effective management of tissue integration and immunological responses to transplants decisively co-determines the success of soft and hard tissue reconstruction. The aim of this in vivo study was to evaluate the eligibility of extracorporeal shock wave therapy (ESWT) with respect to its ability to modulate angiogenesis and immune response to a collagen matrix (CM) for tissue engineering in the chorioallantoic membrane (CAM) assay, which is performed with fertilized chicken eggs. CM were placed on the CAM on embryonic development day (EDD) 7

Vascular Endothelial Growth Factor A0301 basic medicineAngiogenesismedicine.medical_treatmentNitric Oxide Synthase Type IIChick EmbryoChorioallantoic Membranelcsh:ChemistryNeovascularizationangiogenesischemistry.chemical_compoundmacrophage response0302 clinical medicineTissue engineeringlcsh:QH301-705.5Spectroscopyoral inflammationTissue Scaffoldsvascular endothelial growth factorGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorChorioallantoic membraneExtracorporeal shockwave therapyCollagenmedicine.symptomchorioallantoic membrane assayNeovascularization PhysiologicArticleCatalysisAvian ProteinsInorganic ChemistryAndrology03 medical and health sciencesImmune systemIn vivomatrix metalloproteasesmucoderm®medicineAnimalsddc:610Physical and Theoretical Chemistrymucoderm<sup>®</sup>Molecular BiologyTissue Engineeringbusiness.industryOrganic Chemistrycollagen matrix030206 dentistryextracorporeal shockwave therapyHypoxia-Inducible Factor 1 alpha SubunitMatrix Metalloproteinases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistrybusiness
researchProduct

Comparison of growth &amp; function of endothelial progenitor cells cultured on deproteinized bovine bone modified with covalently bound fibronectin …

2016

Objectives The objective of this study was to assess and compare the growth and function of Endothelial Progenitor Cells (EPCs) cultured on covalently bonded Vascular Endothelial Growth Factor (VEGF) and covalently bonded Fibronectin (FN) coating on deproteinized bovine bone (DBB) (test samples), compared to non-modified DBB blocks (control sample). Materials and methods The test samples were prepared by plasma polymerization of allylamine onto DBB blocks. Group1 of test samples were prepared with VEGF coating (VEGF-DBB) where as the Group2 test samples were coated with FN (FN-DBB). Non-modified DBB blocks served as a Control. EPCs were isolated and cultivated from buffy coats of peripheral…

Vascular Endothelial Growth Factor ANitric Oxide Synthase Type IIIAngiogenesis0206 medical engineeringNitric Oxide Synthase Type IICell CountEnzyme-Linked Immunosorbent Assay02 engineering and technologyReal-Time Polymerase Chain ReactionCell morphologyAllylamine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosAnimalsHumansMTT assayProgenitor cellCells CulturedCell ProliferationEndothelial Progenitor CellsMicroscopy Confocalbiology030206 dentistrybiology.organism_classification020601 biomedical engineeringMolecular biologyFibronectinsVascular endothelial growth factorFibronectinchemistryBone SubstitutesImmunologybiology.proteinCattleOral SurgeryClinical Oral Implants Research
researchProduct

Priming with a combination of proangiogenic growth factors improves wound healing in normoglycemic mice

2011

Growth factors and/or angiogenic factors are supposed to improve wound healing. The aim of our study was to evaluate the effects of subcutaneous pretreatment with combinatory proangiogenic factors on wound closure, mechan - ical properties, vessel density and morphology. Twenty-eight Balb/c mice were divided equally into two groups. A mixture of VEGF (35.0 µg), bFGF (2.5 µg) and P dGF (3.5 µg) was administered subcutaneously 3, 5 and 7 days to 14 mice before full thickness skin punch biopsy wounding, whereas 14 control animals received three injections of 0.2 ml saline solution. Wound sizes were assessed daily and the repaired tissues were harvested 7 days after complete wound closure. Comp…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyPlatelet-derived growth factormedicine.medical_treatmentInjections SubcutaneousUrologyPriming (immunology)Neovascularization PhysiologicArticlechemistry.chemical_compoundMiceSkin Physiological PhenomenaTensile StrengthGeneticsmedicineAnimalsRegenerationSalineSkinPlatelet-Derived Growth FactorMice Inbred BALB CWound HealingOncogeneintegumentary systembusiness.industryGeneral MedicineMolecular medicineSurgeryVascular endothelial growth factor ADrug CombinationsCollagen Type IIIchemistryApoptosisThermographyBlood VesselsAngiogenesis Inducing AgentsFemaleFibroblast Growth Factor 2Wound healingbusiness
researchProduct

Regulation of NOS expression in vascular diseases

2020

Nitric oxide synthases (NOS) are the major sources of nitric oxide (NO), a small bioactive molecule involved in the regulation of many cellular processes. One of the most prominent functions of NO is regulation of vasodilatation and thereby control of blood pressure. Most important for vascular tone is NOS3. Endothelial NOS3-generated NO diffuses into the vascular smooth muscle cells, activates the soluble guanylate cyclase resulting in enhanced cGMP concentrations and smooth muscle cell relaxation. However, more and more evidence exist that also NOS1 and NOS2 contribute to vascular function. We summarize the current knowledge about the regulation of NOS expression in the vasculature by tra…

Vascular smooth muscleNitric Oxide Synthase Type IIINOS1CellNitric Oxide Synthase Type IIBlood PressureVasodilationInflammationNitric Oxide Synthase Type INitric OxideMuscle Smooth VascularNitric oxidechemistry.chemical_compoundmedicineAnimalsHumansProtein IsoformsVascular DiseasesRNA Processing Post-TranscriptionalInflammationRegulation of gene expressionInnate immune systemAtherosclerosisImmunity InnateCell biologyGene Expression Regulation Neoplasticmedicine.anatomical_structurechemistryNitric Oxide Synthasemedicine.symptomProtein Processing Post-TranslationalFrontiers in Bioscience-Landmark
researchProduct

Radio Emission from SN 2001gd in NGC 5033

2003

We present the results of monitoring the radio emission from the Type IIb supernova SN 2001gd between 2002 February 8 and 2002 October 28. Most of the data were obtained using the Very Large Array at the five wavelengths of $\lambda \lambda$1.3 cm (22.4 GHz), 2.0 cm (14.9 GHz), 3.6 cm (8.44 GHz), 6.2 cm (4.86 GHz), and 21 cm (1.4 GHz). Observations were also made with Giant Meterwave Radio Telescope at $\lambda$21 cm (1.4 GHz). The object was discovered optically well after maximum light, making any determination of the early radio evolution difficult. However, subsequent observations indicate that the radio emission has evolved regularly in both time and frequency and is well described by …

Very large arrayRadio telescopePhysicsSupernovaWavelengthType iibSpace and Planetary ScienceAstrophysics (astro-ph)FOS: Physical sciencesAstronomy and AstrophysicsAstrophysicsAstrophysics
researchProduct